AIM ImmunoTech Inc

NYSE American: AIM    
Share price (5/10/24): $0.40    
Market cap (5/10/24): $20.3 million

Underwriting Agreements Filter

EX-1
from SC 13D/A 4 pages Kellner Group to Proceed With AIM Director Nominations and Proxy Solicitation Kellner Files Complaint in Delaware Court of Chancery to Enforce Stockholder Rights Stockholders Should Not Be Distracted by Misleading Statements by AIM Kellner Group Nominees Have Skills, Experience and Credibility Necessary for AIM to Be Successful Entrenched AIM Board Continues to Waste Corporate Cash and Resources in Attempt to Avoid Accountability to Stockholders
12/34/56
EX-1
from SC 13D 1 page Joint Filing Agreement
12/34/56
EX-1.1
from 8-K 60 pages Underwriting Agreement Between AIM ImmunoTech Inc. and A.G.P./ALLIANCE Global Partners, as Representative of the Several Underwriters AIM ImmunoTech Inc. Underwriting Agreement
12/34/56
EX-1.1
from S-1/A 47 pages Underwriting Agreement Between AIM ImmunoTech Inc. and A.G.P./ALLIANCE Global Partners, as Representative of the Several Underwriters AIM ImmunoTech Inc. Underwriting Agreement
12/34/56
EX-1.1
from S-1/A 38 pages Hemispherx Biopharma, Inc. Dealer-Manager Agreement
12/34/56
EX-1.1
from 8-K 8 pages 1. Securities. the Term “Securities”, as Used Herein, Shall Be Defined as and Include the Issuance Of, or Reference To, Client’s Common Stock, Debt, Equity or Debt Instruments Convertible Into Client’s Common Stock, Units, Warrants, Additional Investment Rights, Block Trade Transactions or the Exercise of Warrants or Options. 2. Transaction(s). the Term “Transaction” or “Transactions”, as Used Herein, Shall Be Defined as and Include the Sale, Private or Public Offering, Placement, Pledge or Issuance of Client’s Securities and/or Securities Owned by the Officers, Directors and/or Affiliates (“Insiders”) of Client, to Any Institutional and/or Accredited Investor(s). the Actual Terms and Structure of Each Transaction Will Depend on Market Conditions and Will Be Subject to Negotiation Between the Client, Ascendiant, and Prospective Investors. 3. Investor(s) the Term “Investor” or “Investors”, as Used Herein, Shall Be Defined as and Include Any Natural Persons, Corporations, Limited Liability Companies, Partnerships, Unincorporated Businesses, Sole Proprietorships and Similar Entities, and Any and All Related Affiliates for Which the Investors Maintain Direct or Indirect Control, That Are Listed in an Exhibit B to This Agreement
12/34/56
EX-1
from 8-A12B 52 pages Hemispherx Biopharma, Inc. and American Stock Transfer & Trust Company, LLC, Rights Agent Amended and Restated Rights Agreement Dated as of November 14, 2017
12/34/56
EX-1.1
from 8-K 7 pages January 13, 2017 Strictly Confidential Hemispherx Biopharma, Inc. 1617 Jfk Blvd., Suite 500 Philadelphia Pa 19103 Attn: Thomas K. Equels, President, Chief Executive Officer Dear Mr. Equels
12/34/56
EX-1.1
from 8-K 7 pages August 26, 2016 Strictly Confidential Hemispherx Biopharma, Inc. 1617 Jfk Blvd., Suite 500 Philadelphia Pa 19103 Attn: Thomas K. Equels, President, Chief Executive Officer Dear Mr. Equels
12/34/56
EX-1.1
from 10-Q 4 pages Rodman & Renshaw May 8, 2009
12/34/56
EX-1
from POS AM 1 page Underwriting agreement
12/34/56
EX-1
from 10-Q ~20 pages Form of Warrant for Common Stock
12/34/56
EX-1
from PRE 14A 1 page Underwriting agreement
12/34/56
EX-1
from 8-K 1 page Press Release 3-15-2004
12/34/56
EX-1
from 8-A12G ~50 pages Exhibit 1 - Rights Agreement
12/34/56
EX-1
from SC 13G/A 1 page Underwriting agreement
12/34/56
EX-1
from SC 13G/A 1 page Underwriting agreement
12/34/56